Mega Lifesciences (MEGA) investor relations material

Executive summary

• Revenue for Q1 2026 reached THB 3.4 billion, up 14.4% YoY, driven by strong double-digit growth in Branded business and high single-digit growth in Distribution, with Myanmar showing notable recovery.

• Branded business revenue grew 16.5% YoY to THB 2.3 billion, while Distribution business revenue rose 7.8% YoY to nearly THB 1 billion.

• Net profit attributable to owners was THB 604.5 million, up 34% YoY from THB 449.8 million in Q1 2025.

• EBITDA increased 42% YoY to THB 869 million, reflecting margin expansion and operating leverage.

• Total comprehensive income for the period was THB 721 million, compared to THB 441.4 million in Q1 2025.

Financial highlights

• Gross profit margin improved to 52.3% from 51.4% YoY, mainly due to favorable segment mix.

• Branded business gross margin was 66.1% (vs. 65% YoY); Distribution business gross margin was 22% (vs. 23% YoY).

• SG&A expenses rose 6.2% YoY to THB 1,050 million, but as a percentage of revenue, fell from 33% to 31%.

• Basic earnings per share rose to 0.69 Baht from 0.52 Baht YoY.

• Cash and cash equivalents increased to THB 4,281 million as of 31 March 2026.

Outlook and guidance

• Branded business guidance maintained at 8%-12% revenue growth for FY2026, with momentum suggesting the upper end is achievable.

• Distribution business expected to deliver 8%-10% growth for FY2026, with Myanmar recovery supporting the trend.

• Gross margin guidance for Branded business remains at 63%-65%, and 20%-23% for Distribution.

• CapEx plan of THB 2.6 billion over 2026-2028 for manufacturing expansion in Vietnam, Indonesia, and Myanmar.

• Strong operating cash flows and increased profitability indicate positive momentum for upcoming quarters.